Erratum: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (Cancer Cell (2015) 27(1) (85–96) (S1535610814004577) (10.1016/j.ccell.2014.11.006));Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma

Cancer Cell

Volumn 27, Issue 1, 2015, Pages 85-96

  Girotti, Maria Romina ^a   Lopes, Filipa ^b   Preece, Natasha ^b   Niculescu Duvaz, Dan ^b   Zambon, Alfonso ^b   Davies, Lawrence ^b   Whittaker, Steven ^b   Saturno, Grazia ^a   Viros, Amaya ^a   Pedersen, Malin ^b   Suijkerbuijk, Bart M J M ^b   Menard, Delphine ^b   McLeary, Robert ^b   Johnson, Louise ^b   Fish, Laura ^b   Ejiama, Sarah ^a   Sanchez Laorden, Berta ^a   Hohloch, Juliane ^a   Carragher, Neil ^c   Macleod, Kenneth ^c   Ashton, Garry ^a   Marusiak, Anna A ^a   Fusi, Alberto ^d   Brognard, John ^a   Frame, Margaret ^c   Lorigan, Paul ^d   Marais, Richard ^a   Springer, Caroline ^b   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CCT 196969; CCT 241161; DABRAFENIB; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE P60; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; 1-(3-TERT-BUTYL-1-PHENYL-1H-PYRAZOL-5-YL)-3-(2-(METHYLTHIO)-4-(3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZIN-8-YLOXY)PHENYL)UREA; 1-(3-TERT-BUTYL-1-PHENYL-1H-PYRAZOL-5-YL)-3-(2-FLUORO-4-(3-OXO-3,4-DIHYDROPYRIDO(3,2-B)PYRAZIN-8-YLOXY)PHENYL)UREA; ANTINEOPLASTIC AGENT; B RAF KINASE; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FOOD INTAKE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TACHYPNEA; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZINES; SRC-FAMILY KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922223009     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.02.007     Document Type: Erratum

References (39)

1. Ackerman, A., Klein, O., McDermott, D.F., Wang, W., Ibrahim, N., Lawrence, D.P., Gunturi, A., Flaherty, K.T., Hodi, F.S., Kefford, R., et al. (2014). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120, 1695-1701.
2. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C.J., McLauchlan, H., Klevernic, I., Arthur, J.S., Alessi, D.R., and Cohen, P. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315.
3. Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al.; BRIM-3 Study Group (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
4. Dhomen, N., Reis-Filho, J.S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294-303.
5. Fedorenko, I.V., Paraiso, K.H., and Smalley, K.S. (2011). Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharmacol. 82, 201-209.
6. Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., O'Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P.B. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
7. Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
8. Forsea, A.M., Del Marmol, V., de Vries, E., Bailey, E.E., and Geller, A.C. (2012). Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br. J. Dermatol. 167, 1124-1130.
9. Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer discovery 3, 158-167.
10. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R., Ludlam, M.J., Stokoe, D., Gloor, S.L., Vigers, G., et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435.
11. Heidorn, S.J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J.S., Springer, C.J., Pritchard, C., and Marais, R. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
12. Johannessen, C.M., Boehm, J.S., Kim, S.Y., Thomas, S.R., Wardwell, L., Johnson, L.A., Emery, C.M., Stransky, N., Cogdill, A.P., Barretina, J., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
13. Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., et al. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877-1888.
14. Ménard, D., Niculescu-Duvaz, I., Dijkstra, H.P., Niculescu-Duvaz, D., Suijkerbuijk, B.M., Zambon, A., Nourry, A., Roman, E., Davies, L., Manne, H.A., et al. (2009). Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. J. Med. Chem. 52, 3881-3891.
15. Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E., Galvin, K., Okaniwa, M., Ishikawa, T., and Yoshida, S. (2013). Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 73, 7043-7055.
16. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., Chen, Z., Lee, M.K., Attar, N., Sazegar, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
17. Niculescu-Duvaz, I., Roman, E., Whittaker, S.R., Friedlos, F., Kirk, R., Scanlon, I.J., Davies, L.C., Niculescu-Duvaz, D., Marais, R., and Springer, C.J. (2006). Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J. Med. Chem. 49, 407-416.
18. Niculescu-Duvaz, D., Gaulon, C., Dijkstra, H.P., Niculescu-Duvaz, I., Zambon, A., Ménard, D., Suijkerbuijk, B.M., Nourry, A., Davies, L., Manne, H., et al. (2009). Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J. Med. Chem. 52, 2255-2264.
19. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
20. Shi, H., Moriceau, G., Kong, X., Lee, M.K., Lee, H., Koya, R.C., Ng, C., Chodon, T., Scolyer, R.A., Dahlman, K.B., et al. (2012). Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724.
21. Sosman, J.A., Kim, K.B., Schuchter, L., Gonzalez, R., Pavlick, A.C., Weber, J.S., McArthur, G.A., Hutson, T.E., Moschos, S.J., Flaherty, K.T., et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
22. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
23. Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J.S., Kong, X., Koya, R.C., Flaherty, K.T., et al. (2012a). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.
24. Su, Y., Vilgelm, A.E., Kelley, M.C., Hawkins, O.E., Liu, Y., Boyd, K.L., Kantrow, S., Splittgerber, R.C., Short, S.P., Sobolik, T., et al. (2012b). RAF265 inhibits the growth of advanced human melanoma tumors. Clinical cancer research 18, 2184-2198.
25. Suijkerbuijk, B.M., Niculescu-Duvaz, I., Gaulon, C., Dijkstra, H.P., Niculescu- Duvaz, D., Ménard, D., Zambon, A., Nourry, A., Davies, L., Manne, H.A., et al. (2010). Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group. J. Med. Chem. 53, 2741-2756.
26. Turajlic, S., Furney, S.J., Lambros, M.B., Mitsopoulos, C., Kozarewa, I., Geyer, F.C., Mackay, A., Hakas, J., Zvelebil, M., Lord, C.J., et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207.
27. Van Allen, E.M., Wagle, N., Sucker, A., Treacy, D.J., Johannessen, C.M., Goetz, E.M., Place, C.S., Taylor-Weiner, A., Whittaker, S., Kryukov, G.V., et al. (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109.
28. van Oostrum, J., Calonder, C., Rechsteiner, D., Ehrat, M., Mestan, J., Fabbro, D., and Voshol, H. (2009). Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin. Appl. 3, 412-422.
29. Vergani, E., Vallacchi, V., Frigerio, S., Deho, P., Mondellini, P., Perego, P., Cassinelli, G., Lanzi, C., Testi, M.A., Rivoltini, L., et al. (2011). Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13, 1132-1142.
30. Villanueva, J., Vultur, A., Lee, J.T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A.K., Wubbenhorst, B., Xu, X., Gimotty, P.A., Kee, D., et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
31. Wagle, N., Emery, C., Berger, M.F., Davis, M.J., Sawyer, A., Pochanard, P., Kehoe, S.M., Johannessen, C.M., Macconaill, L.E., Hahn, W.C., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096.
32. Wagle, N., Van Allen, E.M., Treacy, D.J., Frederick, D.T., Cooper, Z.A., Taylor- Weiner, A., Rosenberg, M., Goetz, E.M., Sullivan, R.J., Farlow, D.N., et al. (2014). MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68.
33. Weber, J.S., Kudchadkar, R.R., Yu, B., Gallenstein, D., Horak, C.E., Inzunza, H.D., Zhao, X., Martinez, A.J., Wang, W., Gibney, G., et al. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31, 4311-4318.
34. Whittaker, S., Kirk, R., Hayward, R., Zambon, A., Viros, A., Cantarino, N., Affolter, A., Nourry, A., Niculescu-Duvaz, D., Springer, C., and Marais, R. (2010a). Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci. Transl. Med. 2, 35ra41.
35. Whittaker, S., Ménard, D., Kirk, R., Ogilvie, L., Hedley, D., Zambon, A., Lopes, F., Preece, N., Manne, H., Rana, S., et al. (2010b). A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. Cancer Res. 70, 8036-8044.
36. Wilson, T.R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012). Widespread potential for growthfactor- driven resistance to anticancer kinase inhibitors. Nature 487, 505-509.
37. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133.
38. Workman, P., Aboagye, E.O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D.J., Double, J.A., Everitt, J., Farningham, D.A., Glennie, M.J., et al.; Committee of the National Cancer Research Institute (2010). Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-1577.
39. Zambon, A., Ménard, D., Suijkerbuijk, B.M., Niculescu-Duvaz, I., Whittaker, S., Niculescu-Duvaz, D., Nourry, A., Davies, L., Manne, H.A., Lopes, F., et al. (2010). Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. J. Med. Chem. 53, 5639-5655.